Imaging Neuroinflammation in Individuals with Substance Use Disorders
Overview
Authors
Affiliations
Increasing evidence suggests a role of neuroinflammation in substance use disorders (SUDs). This Review presents findings from neuroimaging studies assessing brain markers of inflammation in vivo in individuals with SUDs. Most studies investigated the translocator protein 18 kDa (TSPO) using PET; neuroimmune markers myo-inositol, choline-containing compounds, and N-acetyl aspartate using magnetic resonance spectroscopy; and fractional anisotropy using MRI. Study findings have contributed to a greater understanding of neuroimmune function in the pathophysiology of SUDs, including its temporal dynamics (i.e., acute versus chronic substance use) and new targets for SUD treatment.
Ginsenoside Rg1 alleviates chronic stress-induced depression in rats by targeting Cx43-YAP axis.
Wang H, Zheng R, Ai Q, Yang S, Yang X, Chen A Acta Pharmacol Sin. 2025; .
PMID: 40055527 DOI: 10.1038/s41401-025-01515-9.
Therapeutic targeting of neuroinflammation in methamphetamine use disorder.
Jeffery N, Mock P, Yang K, Tham C, Israf D, Li H Future Med Chem. 2024; 17(2):237-257.
PMID: 39727147 PMC: 11749361. DOI: 10.1080/17568919.2024.2447226.
Bartos L, Quach S, Zenatti V, Kirchleitner S, Blobner J, Wind-Mark K Clin Cancer Res. 2024; 30(20):4618-4634.
PMID: 39150564 PMC: 11474166. DOI: 10.1158/1078-0432.CCR-24-1563.